Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.2 USD | +4.16% | +2.97% | +30.01% |
Financials (USD)
Sales 2024 * | 3.63M | Sales 2025 * | 6.18M | Capitalization | 1.3B |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -191M | EV / Sales 2024 * | 220 x |
Net cash position 2024 * | 502M | Net cash position 2025 * | 403M | EV / Sales 2025 * | 145 x |
P/E ratio 2024 * |
-8.29
x | P/E ratio 2025 * |
-8.52
x | Employees | 171 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.44% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | +5.07% | ||
1 week | +2.15% | ||
Current month | +9.19% | ||
1 month | -0.99% | ||
3 months | -0.19% | ||
6 months | +115.77% | ||
Current year | +28.97% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 14 M€ | -3.79% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 26.34 | +4.73% | 332 048 |
24-05-21 | 25.15 | -3.27% | 403,796 |
24-05-20 | 26 | +2.60% | 462,605 |
24-05-17 | 25.34 | -1.17% | 438,654 |
24-05-16 | 25.64 | +0.23% | 526,900 |
Delayed Quote Nasdaq, May 22, 2024 at 12:53 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.97% | 1.3B | |
+58.83% | 55.07B | |
-1.52% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+12.09% | 26.28B | |
-21.07% | 18.93B | |
+6.83% | 13.03B | |
+28.50% | 12.26B | |
+26.48% | 12.21B |
- Stock Market
- Equities
- FDMT Stock